- Disease
- Acute myeloid leukemia
- Anemia due to chronic kidney disease (CKD)
- Anemia in Chronic Kidney Disease (CKD) Patients on Dialysis
- Aggressive Systemic Mastocytosis (ASM)
- FLT3 mutation AML
- Myeloproliferative Disorders
- Hyperprolactinemia
- Parkinson's Disease
- Prolactinomas
- Nonalcoholic steatohepatitis (NASH)
- Treat essential thrombocythemia (ET)
- High-risk myelofibrosis
- Positive acute myeloid leukemia
- Chronic graft-versus-host disease
- leukaemia
- Chronic immune (idiopathic) thrombocytopenic purpura
- Hronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- Small lymphocytic lymphoma (SLL)
Related News
-
LuciDarax Side Effects, Clinical Trials & FAQs
Introduction Starting treatment for metastatic pancreatic cancer involves more than understanding how…
2026-10-08
-
LuciDarax (Daraxonrasib) Dosage and Administration: A Patient-Friendly Safety Guide
Introduction Starting an oral cancer treatment can feel overwhelming. Patients may have…
2026-10-08
-
LuciDarax (Daraxonrasib): Understanding Its Role in RAS-Driven Pancreatic Cancer
Introduction A diagnosis of metastatic pancreatic cancer can bring difficult treatment decisions…
2026-10-08
-
LuciDarax (Daraxonrasib) Clinical Trials, Distribution & Value in Precision Oncology
Clinical Trials of LuciDarax (Daraxonrasib) The clinical development of LuciDarax (Daraxonrasib) has…
2026-10-05
-
RASONQUE™(Daraxonrasib): Dosage Instructions, Side Effects, FAQ & Myths
How to Take RASONQUE™ (Daraxonrasib) Safely and Effectively Take it exactly as…
2026-10-03
-
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview When Every…
2026-10-01
